Nordestgaard, Børge G.

Glycated hemoglobin measurement and prediction of cardiovascular disease

Di Angelantonio, E., Gao, P., Khan, H., Butterworth, A. S., Wormser, D., Kaptoge, S., Kondapally Seshasai, S. R., Thompson, A., Sarwar, N., Willeit, P., et al. (2014) · JAMA

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Cited by 231

Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization

Roeseler, E., Julius, U., Heigl, F., Spitthoever, R., Heutling, D., Breitenberger, P., Leebmann, J., Lehmacher, W., Kamstrup, P. R., Nordestgaard, B. G., et al. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 227

A Test in Context: Lipid Profile, Fasting Versus Nonfasting

Nordestgaard, B. G. (2017) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 223

Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease

Jepsen, A.-M. K., Langsted, A., Varbo, A., Bang, L. E., Kamstrup, P. R., & Nordestgaard, B. G. (2016) · Clinical Chemistry

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 218

Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM

Langlois, M. R., Nordestgaard, B. G., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H., Borén, J., Bruckert, E., Catapano, A., Cobbaert, C., et al. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM)

Lipoproteins and Cardiovascular HealthClinical Laboratory Practices and Quality Control

Cited by 211

Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population

Varbo, A., Freiberg, J. J., & Nordestgaard, B. G. (2015) · Clinical Chemistry

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 209

Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population

Kamstrup, P. R., & Nordestgaard, B. G. (2016) · JACC: Heart Failure

Lipoproteins and Cardiovascular HealthGenetic Associations and Epidemiology

Cited by 206

Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans.

Shaikh, M., Wootton, R., Nordestgaard, B. G., Baskerville, P., Lumley, J. S., La Ville, A. E., Quiney, J., & Lewis, B. (1991) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology

Cholesterol and Lipid MetabolismAtherosclerosis and Cardiovascular Diseases

Cited by 206

Short telomere length, myocardial infarction, ischemic heart disease, and early death

Weischer, M., Bojesen, S. E., Cawthon, R. M., Freiberg, J. J., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology

Telomeres, Telomerase, and SenescenceGenetic Associations and Epidemiology

Cited by 197

Nonfasting versus fasting lipid profile for cardiovascular risk prediction

Langsted, A., & Nordestgaard, B. G. (2019) · Pathology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 191

Coffee intake and risk of obesity, metabolic syndrome and type 2 diabetes: a Mendelian randomization study

Nordestgaard, A. T., Thomsen, M., & Nordestgaard, B. G. (2015) · International Journal of Epidemiology

Coffee research and impactsGenetic Associations and Epidemiology

Cited by 189

Low LDL cholesterol,PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study

Benn, M., Nordestgaard, B. G., Frikke-Schmidt, R., & Tybjærg-Hansen, A. (2017) · BMJ

Lipoproteins and Cardiovascular HealthDementia and Cognitive Impairment Research

Cited by 178

VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins

Balling, M., Afzal, S., Varbo, A., Langsted, A., Davey Smith, G., & Nordestgaard, B. G. (2020) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 175

Low nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study

Thomsen, M., Varbo, A., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2014) · Clinical Chemistry

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 171

Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a)

Cho, L., Nicholls, S. J., Nordestgaard, B. G., Landmesser, U., Tsimikas, S., Blaha, M. J., Leitersdorf, E., Lincoff, A. M., Lesogor, A., Manning, B., et al. (2025) · American Heart Journal

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 169

Telomere shortening unrelated to smoking, body weight, physical activity, and alcohol intake: 4,576 general population individuals with repeat measurements 10 years apart

Weischer, M., Bojesen, S. E., & Nordestgaard, B. G. (2014) · PLoS Genetics

Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model Organisms

Cited by 167

Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study

Langsted, A., & Nordestgaard, B. G. (2011) · Clinical Chemistry

Diabetes, Cardiovascular Risks, and LipoproteinsLipoproteins and Cardiovascular Health

Cited by 160

Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer

Mellby, L. D., Nyberg, A. P., Johansen, J. S., Wingren, C., Nordestgaard, B. G., Bojesen, S. E., Mitchell, B. L., Sheppard, B. C., Sears, R. C., & Borrebaeck, C. A. K. (2018) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 159

Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants.

Nordestgaard, B. G., Tybjaerg-Hansen, A., & Lewis, B. (1992) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology

Cholesterol and Lipid MetabolismAtherosclerosis and Cardiovascular Diseases

Cited by 159

Plasma levels of apolipoprotein Eand risk of dementia in the general population

Rasmussen, K. L., Tybjærg‐Hansen, A., Nordestgaard, B. G., & Frikke‐Schmidt, R. (2015) · Annals of Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 156

Genetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects

Johannsen, T. H., Frikke-Schmidt, R., Schou, J., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2012) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthParaoxonase enzyme and polymorphisms

Cited by 156

Heterozygous Lipoprotein Lipase Deficiency: Frequency in the General Population, Effect on Plasma Lipid Levels, and Risk of Ischemic Heart Disease

Nordestgaard, B. G., Abildgaard, S., Wittrup, H. H., Steffensen, R., Jensen, G., & Tybjærg-Hansen, A. (1997) · Circulation

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 146

Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population

Varbo, A., & Nordestgaard, B. G. (2019) · Annals of Neurology

Lipoproteins and Cardiovascular HealthAcute Ischemic Stroke Management

Cited by 145

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 140